Neuropathy News and Research

RSS

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Amputations due to diabetes can be prevented

Taking a minute or two every day to inspect your feet and observing a few simple rules can make the difference in sparing diabetes patients from a preventable outcome of the disease a foot amputation.

4 Nov 2004

Test used to diagnose B12 deficiency may be inadequate

A test that generally is used to measure the amount of vitamin B12 in the body is not sensitive enough to detect a deficiency of the vitamin, which has been linked to several neurological conditions, according to Saint Louis University research.

28 Oct 2004

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

The antidepressant Cymbalta (duloxetine HCl), a dual-reuptake inhibitor of serotonin and norepinephrine, 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology.

18 Oct 2004

Some patients who undergo treatment considered to be the last resort for severe obesity can develop peripheral neuropathy

Researchers from Mayo Clinic have found some patients who undergo a treatment considered to be the last resort for those who suffer from severe obesity - stomach stapling or gastric bypass surgery, can develop peripheral neuropathy, damage to the peripheral nerves, the vast communications network that transmits information from the brain and spinal cord to every other part of the body.

16 Oct 2004

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

One group of drugs that is effective in fighting HIV may, paradoxically, also be promoting the death of sensory nerves in the skin, according to a study presented October 5, 2004, at the 129th annual meeting of the American Neurological Association in Toronto.

5 Oct 2004

Neurologists have discovered a drug application smart enough to alleviate orthostatic hypotension

Mayo Clinic neurologists have discovered a drug application smart enough to alleviate orthostatic hypotension -- problems with sinking blood pressure when standing up from a sitting position -- without the unwanted effect of also causing patients' blood pressure to soar when lying down.

5 Oct 2004

Findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes

Eli Lilly and Company have announced key findings from analyses of prior study data that enhances understanding of vision loss due to diabetic retinopathy, a diabetic microvascular complication that affects an estimated 50 million people worldwide.

10 Sep 2004

Cymbalta approved for diabetic peripheral neuropathy pain

The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.

8 Sep 2004

Exubera shows sustained blood glucose control in patients with type 2 diabetes

New data showed that Exubera (inhaled insulin) was effective and well tolerated in controlling blood glucose levels over a two-year period in patients with Type 2 diabetes.

8 Sep 2004

New biotech alliance to focus on diseases of nerve injury and pain

NeuroTargets Ltd, a discovery-led biotechnology company ‘spun-out’ from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain.

11 Aug 2004

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Results from a three year double-blinded trial which compared antiretroviral therapies show that the combination regimens of tenofovir DF and stavudine, are equally effective, though tenofovir DF has more favorable outcomes with respect to cholesterol levels and the nervous system.

11 Jul 2004

Exercise helps overweight men with erectile dysfunction

Erectile dysfunction is known to decrease the quality of life in men, and may affect as many as 30 million men in the United States alone, according to the new study. In a previous study, moderate-to-severe erectile dysfunction was reported by 12 percent of men below the age of 59; 22 percent of men aged 60 to 69 years; and 30 percent of 69 years and older.

22 Jun 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients, researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

7 Jun 2004

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

Closer to understanding the function of a protein linked to an inherited form of the movement disorder dystonia

The protein, torsinA, is defective in patients with DYT1 dystonia, an inherited condition that causes uncontrollable movements in the limbs and torso. Learning what torsinA does could be an important step toward developing a treatment for the disorder.

19 May 2004

Studies show pregabalin does not affect male reproductivity or interfere with oral contraceptives

Two studies presented today at the American Academy of Neurology (AAN) 56th Annual Meeting show that pregabalin, when used as an add-on treatment for epilepsy, does not affect male reproductive function or interfere with the effectiveness of oral contraceptives.

29 Apr 2004

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.

23 Mar 2004

Neuropathy News and Research

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Amputations due to diabetes can be prevented

Test used to diagnose B12 deficiency may be inadequate

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

Some patients who undergo treatment considered to be the last resort for severe obesity can develop peripheral neuropathy

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

Neurologists have discovered a drug application smart enough to alleviate orthostatic hypotension

Findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes

Cymbalta approved for diabetic peripheral neuropathy pain

Exubera shows sustained blood glucose control in patients with type 2 diabetes

New biotech alliance to focus on diseases of nerve injury and pain

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Exercise helps overweight men with erectile dysfunction

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

Closer to understanding the function of a protein linked to an inherited form of the movement disorder dystonia

Studies show pregabalin does not affect male reproductivity or interfere with oral contraceptives

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News